×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster ...
Yahoo Finance
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study...
2 days ago
Purple Biotech's Cancer Study Shows Promise - TipRanks.com
Tipranks
Purple Biotech Ltd. has announced promising interim results from a Phase 2 study of its pancreatic cancer treatment, CM24, which will be...
2 days ago
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
KRON4
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT),...
1 month ago
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Yahoo Finance
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines...
1 month ago
NT219 Plus Cetuximab Demonstrates Efficacy, Tolerability in SCCHN
OncLive
NT219 in combination with cetuximab was safe and effective in patients with recurrent/metastatic squamous cell carcinoma of the head and...
1 month ago
We're A Little Worried About Purple Biotech's (TLV:PPBT) Cash Burn Rate
Simply Wall St
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn.
1 month ago
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
InvestorPlace
PPBT stock results show that Purple Biotech met analyst estimates for earnings per share the fourth quarter of 2023.
1 month ago
Purple Biotech's Phase 2 pancreatic cancer study selected as presentation - TipRanks.com
Tipranks
Purple Biotech (PPBT) announced that interim results from its randomized, controlled, open label, multicenter Phase 2 study of CM24,...
2 days ago
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
GlobeNewswire
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 · Poster Details: Title: NT219, a dual inhibitor of IRS1/2 and STAT3,...
1 month ago
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
GlobeNewswire
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial. December 14, 2023 06:50 ET | Source: Purple Biotech Ltd.
4 months ago